Duhay Francis sold $123 of NVNO

enVVeno Medical (NASDAQ:NVNO) CEO Robert Berman presented at the Virtual Investor 'Why Now' conference, highlighting the company's enVVe treatment for severe Deep Venous Insufficiency and FDA IDE approval for a U.S. pivotal study. The TAVVE trial, starting in Q4 2026, aims to enroll 230 patients and is a key step toward potential regulatory approval. The webcast is available on-demand.

enVVeno Medical (NASDAQ:NVNO) reported Q2 2026 results and said the FDA granted IDE approval to start its TAVVE pivotal trial for its enVVe System. The company expects enrollment to begin in H2 2026 with about 230 patients across up to 40 sites. Cash and investments were about $21.5M at June 30, 2026, with Q2 net loss of $3.6M.

enVVeno Medical (NASDAQ:NVNO) said the U.S. Patent Office issued U.S. Patent No. 12,575,932 covering components and use methods of its enVVe transcatheter replacement venous valve system for deep venous insufficiency. The company links this to prior FDA IDE approval for its TAVVE pivotal trial, with enrollment to start and first patient data expected by end of Q4 2026.

Sentonas Michael (PRESIDENT) sold 49,863 shares of CrowdStrike Holdings, Inc. (CRWD) at an average of $231.74 ($231.61–$242.64, $11.56M total) across 3 trades on 2026-09-21.

Slootman Frank sold 300,000 shares of Snowflake Inc. (SNOW) at an average of $334.49 ($330.16–$338.99, $100.35M total) across 18 trades over 2026-09-18 to 2026-09-21 under a Rule 10b5-1 trading plan.

STEVENS MARK A sold 1,366,000 indirectly-held shares of NVIDIA CORP (NVDA) at an average of $219.73 ($219.72–$220.42, $300.15M total) across 2 trades on 2026-09-18.